Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 865

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 7A
Chunk 865
---
.

 The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase 369,500 shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.

 The Company granted options
to purchase 1,850,000 shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.

During the years ended June 30,
2025 and 2024, the Company granted options to purchase 362,904 and 424,412 shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.

During the years ended June
30, 2025 and 2024, the Company granted options to purchase 0 zero and 329,729
shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the 2019 and
2023 Plan.

During the years ended June 30,
2025, and 2024, the Company granted options to purchase zero and 10,000 shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.

On November 4, 2024, the Company
issued 58,500 stock options to its former interim Chief Financial Officer. The options had a fair value of $31,005 on the
grant date, fully vest on January 6, 2025 and expire on November 4, 2034. Subsequently, during the period ended March 31, 2025,
pursuant to the Company’s executive officer compensation claw back policy, the board of directors directed the Company to claw back
and cancel the 58,500 options which were issued on November 4, 2024.

    F-25

On August 23, 2024, Avram